# EDGAR Filing Document

**Accession Number:** 0001056807
**File Stem:** 0000921895-25-002471
**Filing Date:** 2025-8
**Character Count:** 20277
**Document Hash:** 492a6c2cea49e7c6bcbec8f63cd789e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002471.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000921895-25-002471

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BVF INC/IL
- **CENTRAL INDEX KEY:** 0001056807

**ORGANIZATION NAME:**
- **EIN:** 943184501
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-06800
- **FILM NUMBER:** 251281152

**BUSINESS ADDRESS:**
- **STREET 1:** 44 MONTGOMERY STREET
- **STREET 2:** 40TH FL
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104
- **BUSINESS PHONE:** 3125066500

**MAIL ADDRESS:**
- **STREET 1:** 44 MONTGOMERY STREET
- **STREET 2:** 40TH FL
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001056807

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** BVF INC/IL

**Address:** 44 MONTGOMERY STREET, SAN FRANCISCO, CA 94104

**Telephone number:** 415-525-8830

**Name of agent for service:** James Kratky

**Agent Address:** BVF Inc., San Francisco, CA 94104

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-06800

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                  | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                     | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| CIDARA THERAPEUTICS, INC.       | 171757206 | 07/18/2024     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         343055 |                0 | FOR         | 343055                                   | FOR                         |  |
| VISTAGEN THERAPEUTICS, INC.     | 92840H400 | 08/26/2024     | To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers.                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        2000000 |                0 | FOR         | 2000000                                  | FOR                         |  |
| ROIVANT SCIENCES LTD.           | G76279101 | 09/10/2024     | To cast a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ROIVANT SCIENCES LTD.           | G76279101 | 09/10/2024     | To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every:                                                                                       | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| MOLECULAR TEMPLATES, INC.       | 608550208 | 09/27/2024     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         522238 |                0 | FOR         | 522238                                   | FOR                         |  |
| PIERIS PHARMACEUTICALS, INC.    | 720795202 | 12/02/2024     | Approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         257626 |                0 | FOR         | 257626                                   | FOR                         |  |
| ZYMEWORKS INC.                  | 98985Y108 | 12/10/2024     | Advisory Vote on the compensation of our named executive officers                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        4308935 |                0 | FOR         | 4308935                                  | FOR                         |  |
| ESSA PHARMA INC.                | 29668H708 | 03/05/2025     | The approval, on a non-binding, advisory basis, of the compensation paid to the Company's named executive officers.                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| CELCUITY INC.                   | 15102K100 | 05/13/2025     | To approve, by a non-binding and advisory vote, compensation of the named executive officers.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| VERASTEM, INC.                  | 92337C203 | 05/22/2025     | To approve an advisory vote on the compensation of the named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        2100468 |                0 | FOR         | 2100468                                  | FOR                         |  |
| MIRUM PHARMACEUTICALS, INC.     | 604749101 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        2761333 |                0 | FOR         | 2761333                                  | FOR                         |  |
| IONIS PHARMACEUTICALS, INC.     | 462222100 | 06/05/2025     | To make an advisory vote on executive compensation.                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |        1913385 |                0 | FOR         | 1913385                                  | FOR                         |  |
| ANNEXON, INC.                   | 03589W102 | 06/05/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        7000000 |                0 | FOR         | 7000000                                  | FOR                         |  |
| KURA ONCOLOGY, INC.             | 50127T109 | 06/05/2025     | Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        7754129 |                0 | FOR         | 7754129                                  | FOR                         |  |
| VERVE THERAPEUTICS, INC.        | 92539P101 | 06/05/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        6904050 |                0 | FOR         | 6904050                                  | FOR                         |  |
| MOONLAKE IMMUNOTHERAPEUTICS     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |       19751284 |                0 | FOR         | 19751284                                 | FOR                         |  |
| GLYCOMIMETICS, INC.             | 38000Q102 | 06/05/2025     | Approve, on an advisory basis, certain compensation arrangements for GlycoMimetics' named executive officers that are based on or otherwise relate to the Merger.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        9544262 |                0 | FOR         | 9544262                                  | FOR                         |  |
| GLYCOMIMETICS, INC.             | 38000Q102 | 06/05/2025     | Approve, on an advisory basis, the compensation of GlycoMimetics' named executive officers.                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |        9544262 |                0 | FOR         | 9544262                                  | FOR                         |  |
| AXSOME THERAPEUTICS, INC.       | 05464T104 | 06/06/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |        1690221 |                0 | FOR         | 1690221                                  | FOR                         |  |
| PALVELLA THERAPEUTICS, INC      | 697947109 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |         257626 |                0 | 1-YR        | 257626                                   | FOR                         |  |
| OLEMA PHARMACEUTICALS, INC.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |        5295893 |                0 | FOR         | 5295893                                  | FOR                         |  |
| CYTOMX THERAPEUTICS, INC.       | 23284F105 | 06/11/2025     | To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;                                               | SECTION 14A SAY-ON-PAY VOTES |        5228461 |                0 | FOR         | 5228461                                  | FOR                         |  |
| TENAX THERAPEUTICS, INC.        | 88032L605 | 06/11/2025     | Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         339549 |                0 | FOR         | 339549                                   | FOR                         |  |
| TENAX THERAPEUTICS, INC.        | 88032L605 | 06/11/2025     | Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         339549 |                0 | 2-YR        | 339549                                   | FOR                         |  |
| XENCOR, INC.                    | 98401F105 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        2740141 |                0 | FOR         | 2740141                                  | FOR                         |  |
| CULLINAN THERAPEUTICS, INC.     | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, to approve our named executive officer compensation.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        5750683 |                0 | FOR         | 5750683                                  | FOR                         |  |
| CULLINAN THERAPEUTICS, INC.     | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |        5750683 |                0 | 1-YR        | 5750683                                  | FOR                         |  |
| REPARE THERAPEUTICS INC.        | 760273102 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement.                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |       10333600 |                0 | FOR         | 10333600                                 | FOR                         |  |
| 4D MOLECULAR THERAPEUTICS, INC. | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        4585983 |                0 | FOR         | 4585983                                  | FOR                         |  |
| 4D MOLECULAR THERAPEUTICS, INC. | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        4585983 |                0 | 1-YR        | 4585983                                  | FOR                         |  |
| AVALO THERAPEUTICS INC          | 05338F306 | 06/17/2025     | To approve, on a nonbinding advisory basis, a "Say-on-Pay" resolution regarding the compensensation of our named executive officers;                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |        1028049 |                0 | FOR         | 1028049                                  | FOR                         |  |
| CIDARA THERAPEUTICS, INC.       | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         557061 |                0 | FOR         | 557061                                   | FOR                         |  |
| PROTAGONIST THERAPEUTICS, INC.  | 74366E102 | 06/20/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        2575015 |                0 | FOR         | 2575015                                  | FOR                         |  |
| STRUCTURE THERAPEUTICS, INC.    | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        1699655 |                0 | FOR         | 1699655                                  | FOR                         |  |
| STRUCTURE THERAPEUTICS, INC.    | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        1771417 |                0 | 1-YR        | 1771417                                  | FOR                         |  |
| KYMERA THERAPEUTICS, INC.       | 501575104 | 06/25/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers;                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |        4607955 |                0 | FOR         | 4607955                                  | FOR                         |  |
| REVOLUTION MEDICINES, INC.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). | SECTION 14A SAY-ON-PAY VOTES |        4982384 |                0 | FOR         | 4982384                                  | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** BVF INC/IL

**By (Signature):** /s/ Mark N. Lampert

**By (Printed Signature):** /s/ Mark N. Lampert

**By (Title):** President

**Date:** 08/29/2025